Italfarmaco’s Givinostat Enters Canadian Fast Lane for DMD Treatment

MILAN, Italy & OTTAWA, Canada – June 10, 2026 – In a move that brings a potential new therapy one step closer to the roughly 1,000 boys in Canada living with Duchenne muscular dystrophy (DMD), Italian pharmaceutical firm Italfarmaco announced today that Health Canada has accepted its New Drug Submission for givinostat. More critically, the submission was granted Priority Review status, signaling regulatory belief in the drug's potential to significantly improve on existing treatments and targeting an expedited 180-day review period.

This decision is more than a procedural milestone; it represents a crucial intersection of medical innovation, regulatory efficiency, and corporate strategy. For Canadian families navigating the devastating progression of DMD, it offers a tangible source of hope. For Italfarmaco, a private company with global ambitions, it marks a strategic entry into the complex Canadian pharmaceutical market. And for Canada's healthcare system, it poses a fresh test of its ability to evaluate, approve, and provide access to high-value rare disease therapies.

A New Mechanism Against an Old Foe

Duchenne muscular dystrophy is a relentless genetic disorder, characterized by progressive muscle degeneration that typically leads to loss of ambulation in early adolescence and life-threatening heart and respiratory complications. For decades, the standard of care has been corticosteroids, which can slow decline but come with a heavy burden of side effects like stunted growth and weight gain.

Givinostat, which will be marketed as Duvyzat®, operates on a different axis. It is a histone deacetylase (HDAC) inhibitor, designed to counteract the excessive HDAC activity that stifles muscle repair and regeneration in DMD patients. Its most significant attribute from a market and patient-access perspective is that its mechanism is independent of the specific gene mutation causing the disease. This broad applicability contrasts sharply with exon-skipping therapies that target only small, genetically-defined subsets of the DMD population.

The submission to Health Canada rests on the robust data from the Phase 3 EPIDYS trial, a randomized, double-blind, placebo-controlled study published in The Lancet Neurology. The trial met its primary endpoint, showing a statistically significant and clinically meaningful difference in the time it took for boys treated with givinostat to complete a four-stair climb compared to a placebo group. Over 72 weeks, the givinostat group demonstrated a slower decline, with a mean difference of 1.78 seconds—a critical measure of functional ability.

Key secondary endpoints reinforced this finding. Patients on givinostat experienced a 40% smaller decline in their total score on the North Star Ambulatory Assessment (NSAA), a comprehensive measure of motor function. Furthermore, MRI scans revealed that givinostat reduced the infiltration of fat into the thigh muscle—a key predictor of lost mobility—by 30% compared to placebo. While treatment-related side effects such as decreased platelet counts and increased triglycerides were observed, the study concluded they were manageable with monitoring and dose adjustments.

“Families affected by Duchenne muscular dystrophy in Canada currently have limited access to treatment options that can slow functional decline,” said Dr. Jean K. Mah, a Canadian investigator for the EPIDYS trial and Director of the Pediatric Neuromuscular Program at the Alberta Children’s Hospital. “As a clinician treating DMD patients, I am encouraged by this positive step in the Canadian regulatory progress and givinostat’s therapeutic potential.”

Navigating Canada's Regulatory and Reimbursement Gauntlet

The Priority Review designation from Health Canada is a powerful endorsement. It is reserved for drugs targeting serious conditions that may offer a significant improvement over existing therapies. While the standard review timeline is 300 days, this status cuts the target to just 180 days, reflecting the urgency of the unmet need in the DMD community.

This follows the precedent set in October 2025, when Health Canada approved Agamree (vamorolone), a different type of corticosteroid with a more favorable side-effect profile, also under Priority Review. Together, these decisions suggest an evolving regulatory posture in Canada, one that is increasingly responsive to the need for novel therapies in the rare disease space.

However, regulatory approval is only the first hurdle. The true test for Italfarmaco—and for patients—will be navigating Canada’s fragmented and often challenging reimbursement landscape. Following a potential Health Canada approval, givinostat will face scrutiny from health technology assessment bodies and subsequent negotiations with provincial and territorial drug plans. The high price tag typical of rare disease therapies will undoubtedly be a central point of these discussions.

A Global Strategy with a Canadian Foothold

Italfarmaco’s move is a calculated part of a broader global expansion. Givinostat has already secured approvals in major markets, including the United States (March 2024), the European Union, the United Kingdom, and the United Arab Emirates. This string of international successes de-risks the Canadian submission and demonstrates a well-executed global commercialization plan. Notably, a positive recommendation from the UK's National Institute for Health and Care Excellence (NICE) in May 2026 provides a strong precedent for the drug's cost-effectiveness argument.

As part of its Canadian strategy, Italfarmaco has committed to establishing a local affiliate. This move signals a long-term commitment beyond simply selling a product. A Canadian presence is essential for managing the complex dialogue with regulators, payers, clinicians, and patient organizations.

“Health Canada’s acceptance of the New Drug Submission for givinostat with Priority Review is an encouraging step forward,” said Francesco Di Marco, Chief Executive Officer of Italfarmaco Group. “As we expand our presence in Canada, we are committed to working with clinicians, patient organisations, and other stakeholders to support the Duchenne community.”

For the Canadian DMD community, which has long advocated for more and better treatment options through organizations like Defeat Duchenne Canada, the news is a welcome development. The focus now shifts from clinical promise to regulatory reality, with families and physicians watching closely to see if this new hope can successfully navigate the final steps to become an accessible therapy for those who need it most.